中国临床药理学杂志Issue(6)：500-502,3.DOI:10.13699/j.cnki.1001-6821.2014.06.009
膀胱内灌注丝裂霉素与表柔比星预防膀胱癌术后复发的临床研究
Clinical trial of epirubicin vs mitomycin bladder instillation chemotherapy for the treatment of superficial bladder cancer
摘要
Abstract
Objective To evaluate the clinical efficacy and adverce drug reaction ( ADR ) for epirubicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer ( SBC ).Methods Seventy-eight cases of postsurgical SBC recruited from Apr 2011 to Jan 2013 in our hospital retrospectively.Of the 78 subjects , 31 patients were treated by mitomycin and other 47 cases were treated by epirubicin.The clinical efficacy and ADR of the two groups were recor-ded and compared.Results The median follow-up period of mitomy-cin group was 12.6 months with a recurrence rate of 16.1%( 5/31 ).And the median follow -up period of epirubicin group was 13.2 months with a recurrence rate of 14.7%(7/47).No statistical difference of re-currence of hazard ratio ( HR=1.02 ) was found between the two groups ( P>0.05).Conclusion There were no statistical difference for epiru-bicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer.关键词
丝裂霉素/表柔比星/膀胱癌/灌注化疗/随访Key words
mitomycin/epirubicin/bladder carcinoma/instillation chemotherapy/follow-up period分类
医药卫生引用本文复制引用
李美凤,周小庆,曾菁,罗松涛..膀胱内灌注丝裂霉素与表柔比星预防膀胱癌术后复发的临床研究[J].中国临床药理学杂志,2014,(6):500-502,3.基金项目
泸州医学院-泸州医学院附属中医医院联合科研基金资助项目 （）
